Asset Details
Do you wish to reserve the book?
Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry
Do you wish to request the book?
Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Salivary metabolomic biomarkers for esophageal and gastric cancers by liquid chromatography–mass spectrometry
2024
Overview
Early detection of esophageal and gastric cancers is essential for patients' prognosis; however, optimal noninvasive screening tests are currently not available. Saliva is a biofluid that is readily available, allowing for frequent screening tests. Thus, we explored salivary diagnostic biomarkers for esophageal and gastric cancers using metabolomic analyses. Saliva samples were collected from patients with esophageal (n = 50) and gastric cancer (n = 63), and patients without cancer as controls (n = 20). Salivary metabolites were analyzed by liquid chromatography–mass spectrometry to identify salivary biomarkers. We also examined the metabolic profiles of gastric cancer tissues and compared them with the salivary biomarkers. The sensitivity of the diagnostic models based on salivary biomarkers was assessed by comparing it with that of serum tumor markers. Additionally, using postoperative saliva samples collected from patients with gastric cancer, we analyzed the changes in the biomarkers' concentrations before and after surgery. Cytosine was detected as a salivary biomarker for gastric cancer, and cytosine, 2‐oxoglutarate, and arginine were detected as salivary biomarkers for esophageal cancer. Cytidine, a cytosine nucleotide, showed decreased concentrations in gastric cancer tissues. The sensitivity of the diagnostic models for esophageal and gastric cancers was 66.0% and 47.6%, respectively, while that of serum tumor markers was 40%. Salivary cytosine concentration increased significantly postoperatively relative to the preoperative value. In summary, we identified salivary biomarkers for esophageal and gastric cancers, which showed diagnostic sensitivity at least comparable to that of serum tumor markers. Salivary metabolomic tests could be promising screening tests for these types of cancer. We explored salivary diagnostic biomarkers for esophageal and gastric cancers using liquid chromatography–mass spectrometry. Cytosine was detected as a salivary biomarker for gastric cancer, and cytosine, 2‐oxoglutarate, and arginine were detected as salivary biomarkers for esophageal cancer. The diagnostic ability of the models constructed with the detected biomarkers was at least equivalent to that of serum tumor markers.
Publisher
Wiley,John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aged
/ Antigens
/ Biomarkers, Tumor - analysis
/ Biomarkers, Tumor - metabolism
/ Chromatography, Liquid - methods
/ Cytosine
/ Early Detection of Cancer - methods
/ Esophageal Neoplasms - diagnosis
/ Esophageal Neoplasms - metabolism
/ Female
/ Humans
/ LC‐MS
/ Liquid Chromatography-Mass Spectrometry
/ Male
/ Original
/ Saliva
/ Stomach Neoplasms - diagnosis
/ Stomach Neoplasms - metabolism
/ Surgery
/ Tumors
